BACKGROUND: Little is known about the long-term prognosis of small bowel carcinoids because currently no staging system exists. METHODS: A search of the Surveillance, Epidemiology and End Results (SEER) database identified 6,380 patients with small bowel carcinoid tumors from 1977 to 2004. Patients were analyzed according to various clinicopathologic factors and a tumor (T1, T2, T3), lymph node (N0, N1), and metastasis (M0, M1) staging system was created according to these parameters. RESULTS: Among the 6,380 patients, 2,985 women and 3,395 men, with a median age of 66 years (range 14-98), the median tumor size was 1.9 cm (range .1-30 cm). Multivariate analysis demonstrated that age, size of the primary tumor, and depth of invasion were significant factors. Four stages were created according to statistically significant prognostic factors: 13% of patients were classified into stage I, 31% into stage II, 16% into stage III, and 40% into stage IV. Five-year survival rates were 96%, 87%, 74%, and 43% for stages I through IV, respectively. CONCLUSIONS: The newly developed TNM staging system accurately discriminates prognosis for small bowel carcinoid tumors.
BACKGROUND: Little is known about the long-term prognosis of small bowel carcinoids because currently no staging system exists. METHODS: A search of the Surveillance, Epidemiology and End Results (SEER) database identified 6,380 patients with small bowel carcinoid tumors from 1977 to 2004. Patients were analyzed according to various clinicopathologic factors and a tumor (T1, T2, T3), lymph node (N0, N1), and metastasis (M0, M1) staging system was created according to these parameters. RESULTS: Among the 6,380 patients, 2,985 women and 3,395 men, with a median age of 66 years (range 14-98), the median tumor size was 1.9 cm (range .1-30 cm). Multivariate analysis demonstrated that age, size of the primary tumor, and depth of invasion were significant factors. Four stages were created according to statistically significant prognostic factors: 13% of patients were classified into stage I, 31% into stage II, 16% into stage III, and 40% into stage IV. Five-year survival rates were 96%, 87%, 74%, and 43% for stages I through IV, respectively. CONCLUSIONS: The newly developed TNM staging system accurately discriminates prognosis for small bowel carcinoid tumors.
Authors: Robert C G Martin; David A Kooby; Sharon M Weber; Nipun B Merchant; Alex A Parikh; Clifford S Cho; Syed A Ahmad; Hong Jin Kim; William Hawkins; Charles R Scoggins Journal: J Gastrointest Surg Date: 2010-11-20 Impact factor: 3.452
Authors: Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger Journal: HPB (Oxford) Date: 2010-08 Impact factor: 3.647
Authors: Michelle Kang Kim; Richard R P Warner; Sasan Roayaie; Noam Harpaz; Stephen C Ward; Steven Itzkowitz; Juan P Wisnivesky Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Alexandra Gangi; Emily Siegel; Galinos Barmparas; Simon Lo; Laith H Jamil; Andrew Hendifar; Nicholas N Nissen; Edward M Wolin; Farin Amersi Journal: J Gastrointest Surg Date: 2017-11-08 Impact factor: 3.452